NCT05746845Completed
Implication of 5-HT7 Receptor in Inflammatory Mechanisms in Multiple Sclerosis
RESEPTOR 5-HT7 : Interest of the 5-HT7 Serotonin Receptor as a Biomarker in Multiple Sclerosis
Source: ClinicalTrials.gov · Last updated 23 Dec 2025
Brief summary (registry, in English)
Multiple Sclerosis is a chronic autoimmune disease associated with inflammatory response harmful for the Central Nervous System. Immunological imbalance is involved with Th1 and Th17 cells in correlation with a disturbance of regulators mechanisms as Treg cells. Despite years of research, the mechanisms involved remain unclear. Serotonin (5-HT) seems to be play an essential role in developing CNS inflammatory diseases and in particular in MS. Indeed, several studies have shown the anti-inflammatory potential of this neurotransmitter and also its vulnerability in inflammatory context. Moreover, a recent study has shown that 5-HT can reduced CD4 T cells proliferation and pro-inflammatory cytokines released in vitro. Interestingly, treatment, treatment with SSRIs (selective serotonin reuptake inhibitor) in an animal model of MS, on Experimental Autoimmune Encephalomyelitis, was shown to improve the clinical score and promote remission of the disease. Among serotonin receptors, the 5-HT7 receptor, can be considered as an interesting target to treat neurological disorders associated with inflammatory context. Present in humans and mice, this receptor is expressed on the surface of a large number of cells, such as T-lymphocytes, macrophages, dendritic cells as well as on cells of CNS such as neurons, astrocytes and microglia. Given the importance of the positive cells for 5-HT7 receptor, in the inflammatory context observed in multiple sclerosis, the investigators propose to study the receptor expression in blood samples from multiple sclerosis patient.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 100 (actual)
- First submitted
- 25 Jan 2023
- Start date
- 6 Mar 2023
- Primary completion date
- 1 Jul 2024
- Lead sponsor
- Centre Hospitalier Régional d'Orléans
- Diseases
- Multiple sclerosis
- NCT number
- NCT05746845
What you commit to
- Study type: Observational
- Participants enrolled: 100
- From 6 Mar 2023 to the primary completion date, 1 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient treated with corticosteroids in the last month
Other illness
- HIV serology known or discovered during the present episode
Other
- Demented patient
- Non-affiliated person or non-beneficiary of a social security scheme
- Uncooperative patient
- Patient under legal protection, guardianship or curatorship
- Pregnant or breastfeeding women
Who the study is looking for
- Men and women
- Aged between 18 and 50 years old,
- With multiple sclerosis already diagnosed and fulfilling the modified Mc Donald criteria
- Stable (no relapse in the last 6 months and MRI less than a year old, with no new lesions) and with at least 1 year of treatment with Natalizumab, Ocrelizumab, Teriflunomide or Fumarate
- Subject medically fit to give a maximum of 50 ml of extra whole blood
- Patient having given their consent to participate in the study
Age in the registry: 18 years to 50 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Orléans Coordinator of this site? Confirm its status | Orléans | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.